台寶生醫股份有限公司
  • About Us
    • Company Overview
    • Team
    • Consultant
    • Location
  • Science
    • FAST CGT Platform
    • Pipeline
    • TDM
  • Investors
    • Corporate Governance
      • Board of Directors
        • Board Composition
        • Board Resolutions
        • Board Execution Status
      • Committees
        • Audit Committee
        • Compensation Committee
      • Corporate Governance Officer
      • Major Internal Policies
    • Financials
      • Monthly Revenue
      • Financial Reports
    • Shareholder Services
      • Major Shareholders
      • Meeting Information
      • Stakeholder Contact
      • Prospectuses
      • Material Information
      • Dividend and Stock
    • Investor Conference
        Investor Conference
    • Interested Parties
        Interested Parties
  • ESG
  • Press Center
    • Press Release
    • Public Announcement
  • Contact
  • Language| 繁中 EN
Press Center
  1. Home
  2. Press Center
  3. Press Release
Press Release Public Announcement
202025.03
Press Release
台寶退化性關節炎新藥授權Senectus生效 進軍東南亞市場
142025.03
Press Release
台寶生醫去年每股虧4.81元 抗排斥新藥二期臨床試驗4月開始收案
132025.03
Press Release
攻美製造商機 台寶前進鳳凰城 攜手梅約打造新一代細胞治療產品
222024.12
Press Release
台寶生醫危急性肢體缺血細胞新藥 申請FDA一期臨床試驗
  • 1
台寶生醫股份有限公司
台寶生醫股份有限公司
Taiwan Bio Therapeutics INC.
Taipei ​| Office
5F., No. 501, Sec. 2, Tiding Blvd., Neihu Dist., Taipei City , Taiwan (R.O.C.) +886-2-2695-6382 info@twbio-thera.com
Hsin Chu | Manufacturing Site
4F., No. 66, Shengyi 2nd Rd., Zhubei City, Hsinchu County , Taiwan (R.O.C.) +886-3-6684788#2020 info@twbio-thera.com
About Us Science Investors ESG Press Center Contact
Copyright © 2025 台寶生醫股份有限公司. All Rights Reserved.Design By Choice